Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A pilot study

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Although 3′-deoxy-3′[(18)F]-fluorothymidine (FLT)- positron emission tomography (PET) has been utilized for tumor response assessment to neoadjuvant chemotherapy in soft tissue sarcomas, it has not been exploited for the assessment of early response to systematically targeted therapies. Herein, we investigated the 18F-FLT PET/CT kinetics in patients with sarcoma who received targeted therapies. Among 15 patients with sarcoma who underwent 18F-FLT PET/CT, 5 patients (33%) patients were imaged at three time points: At baseline and at 1–15 weeks (MDM2-inhibitor treatment), and 10 patients (67%) were imaged twice: At baseline and at 1–4 weeks (MDM2 inhibitor, n = 5 ;c-met inhibitor n = 5). The patients with sarcoma had a total of 18 identifiable tumors. Twelve of 15 patients (80%) demonstrated 18F-FLT concentrations changes early, i.e., at 1–4 weeks. Eight patients responded (53.3%), four patients progressed (26.7%) based on FLT change of more than 10% increase, and three patients (20%) demonstrated no change. 18F-FLT PET/CT may be used for early response imaging to molecularly targeted therapies in patients with sarcoma. Further larger studies in specific sarcoma sub-types are warranted.

Original languageEnglish (US)
Article number125
JournalDiagnostics
Volume10
Issue number3
DOIs
StatePublished - Feb 1 2020

Keywords

  • 18F-FLT PET/CT
  • C-met
  • F-FDG PET CT
  • Mdm-2
  • Sarcoma
  • Targeted therapy

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A pilot study'. Together they form a unique fingerprint.

Cite this